摘要
目的 观察新型非去极化肌松药顺式阿曲库铵用于肾移植手术麻醉中的肌松效应与安全性。方法16例终末期肾功能衰竭患者接受肾移植手术,对照组16例肾功能正常患者接受其他手术。麻醉诱导用咪达唑仑、依托咪酯和芬太尼,麻醉维持用N2O:O2（50％:50％）吸入,间断静注咪达唑仑和芬太尼。经肘前静脉注入顺式阿曲库铵0.1mg/kg（2×ED95）,用BIOMETER加速度仪进行肌松监测。结果 顺式阿曲库铵的药效学各项参数在肾功能哀竭患者和肾功能正常患者之间无明显差异（P>0.05）。结论 顺式阿曲库铵能安全地用于肾移植手术的麻醉。
Objective This study was designed to compare the pharmacodynamical profiles of ci-satracurium in normal renal function patients and end - stage renal failure patients undergoing renal transplantation. Methods Sixteen patients with end - stage renal failure undergoing renal transplantation and a control group of 16 patients with normal renal function undergoing elective surgery were selected for study. In all patients anesthesia was induced with midazolam , etomidate , fentanyl, and maintained with N2O: O2 (50%:50% ) with additional midazolam and fentanyl as necessary. Two groups of patients all received cisa-tarcurium 0. 1mg/kg(2×ED95). Neuromuscular blocking effects were monitored using the BIOMETER acce-lograph. The onset time and time to T1 recover to 25% , 75% , 90% and the TOF ratio to 70% were noted. The recovery index (time of T1 recover from 25% to 75% ) was also calculated. Results There were no significant differences in all observed pharmacodynamical parameters of cisatracurium between the renal failure group and the normal controls. Conclusion The pharmacodynamical profiles of cisatracurium in patients with end - stage renal failure were similar to those in patients with normal renal function. Cisatracurium can be safely used in patients undergoing renal transplantation.
出处
《上海第二医科大学学报》
CSCD
2002年第6期517-519,共3页
Acta Universitatis Medicinalis Secondae Shanghai
